NCT00985387已完成不适用
Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,215
- 主要终点
- percentage of patients who are maintaining solifenacin treatment
研究概览
简要总结
The purpose of the study is to assess patient's persistency in maintaining solifenacin treatment for overactive bladder.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Overactive bladder symptoms lasting for more than 3 months
- •The question 3 score of the overactive bladder symptom score(OABSS)≥ 2 and the sum score of OABSS ≥ 3
- •Symptoms of urinary urgency defined as a level of 1 to 2 in a 3-point Urgency Perception Scale (UPS)
排除标准
- •Any condition that would contraindicate their usage of anticholinergic treatment, including: urinary retention, gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis
- •Symptomatic acute urinary tract infection (UTI)
- •Diagnosed or suspected of interstitial cystitis
- •Treatment with anticholinergic drugs for over 3 months within 12 months prior to the study
- •Pregnant or nursing women
- •Treatment within the 14 days before the study or expected to initiate treatment during the study with any anticholinergic drugs other than solifenacin or treatment for overactive bladder with other drugs
- •Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion
研究组 & 干预措施
Solifenacin treatment
Male and female OAB patients who were treated with solifenacin
干预措施: Solifenacin (Drug)
结局指标
主要结局
percentage of patients who are maintaining solifenacin treatment
时间窗: Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12
次要结局
- percentage of patients who discontinued solifenacin treatment(Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12)
- percentage of patients who switched to other OAB medication(Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12)
研究者
相似试验
已完成
4 期
A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 WeeksOveractive BladderNCT00884104KYU-SUNG LEE307
已完成
3 期
A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076Urinary Bladder, OveractiveNCT01655069Astellas Pharma Europe B.V.148
Unknown
4 期
Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)Urinary FrequencyUrinary UrgencyNocturiaNCT00826527Seattle Urology Research Center23
终止
不适用
Study of Diroximel Fumarate in the Real-World SettingRelapsing Forms of MSNCT04746976Biogen75
终止
不适用
Exploring Diroximel Fumarate Real-world Experience in Canada and IsraelRelapsing Forms of MSNCT04948606Biogen64